YOLFTbeta
Mustang Bio Inc

Mustang Bio Inc

MBIO · NASDAQ · Healthcare / Biotechnology

0.4214USD-0.04 (-9.26%)

Price History

Full chart

Market Stats

Previous Close0.4644
Open0.4374
Day Range0.4157 – 0.4469
52-Week Range0.466 – 1.85
Volume19.47K
Market Cap3.94M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.42
Dividend Yield0.00%
Beta2.05
50-Day Avg0.5628
200-Day Avg0.7731

About

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children's hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Manuel Litchman M.D.
  • Employees4
  • Headquarters95 Sawyer Road, Waltham, MA, United States, 02453, USA
  • Websitehttps://www.mustangbio.com

Leadership

  • Mr. Michael S. Weiss Esq., J.D.Executive Chairman · b. 1966
  • Dr. Manuel Litchman M.D.President, CEO, Interim CFO & Director · b. 1954
  • Mr. Peter CarneyController & Interim Chief Accounting Officer · b. 1987
  • Mr. Greg Furrow M.S.Chief Quality Officer
  • Ms. Robyn M. HunterCorporate Secretary · b. 1962

Financials

Income Statement

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue00000000000
Cost of Revenue002.00K630.00K1.37M1.78M2.31M3.03M2.23M823.00K41.00K
Gross Profit00-2.00K-630.00K-1.37M-1.78M-2.31M-3.03M-2.23M-823.00K-41.00K
Operating Expense4.30M-11.36M31.78M30.59M44.52M55.02M64.42M73.13M48.50M15.42M2.39M
Operating Income-4.30M11.36M-31.79M-31.22M-45.88M-56.81M-66.72M-76.16M-50.73M-16.25M-2.43M
EBITDA-4.30M-11.51M-31.28M-30.02M-43.25M-54.31M-64.05M-71.14M-48.06M-14.92M-1.88M
Net Income-4.47M-12.65M-31.29M-30.66M-48.16M-60.02M-66.37M-77.53M-51.60M-15.75M-1.92M
R&D4.04M8.55M20.38M24.46M36.31M45.62M53.54M63.95M39.18M8.42M1.52M
Interest Expense168.00K1.15M8.00K8.00K1.77M3.92M15.00K3.36M1.31M5.00K-

Balance Sheet

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-27.50M63.49M42.75M73.44M109.90M125.17M92.42M17.74M9.31M17.59M
Total Liabilities4.13M3.22M3.66M6.36M21.79M11.46M12.77M46.15M17.62M13.18M8.06M
Total Equity-4.13M24.28M59.83M36.40M51.65M98.44M112.40M46.27M123.00K-3.87M9.53M
Cash-27.50M34.98M16.47M61.41M97.80M109.62M75.66M6.23M6.84M17.27M
Total Debt3.57M320.00K--15.53M2.23M2.03M31.38M2.50M878.00K-
Net Debt3.57M-27.18M-34.98M-16.47M-45.88M-95.58M-107.58M-44.27M-3.74M-5.96M-17.27M

Cash Flow

Currency: USD2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-1.57M-4.13M-12.95M-19.24M-33.58M-37.32M-53.67M-65.07M-49.48M-11.41M-5.26M
Investing Cash Flow-2.00M-29.05M-29.05M557.00K13.91M-4.41M-5.37M-2.95M5.89M-1.17M
Financing Cash Flow3.57M31.63M49.98M181.00K65.12M78.12M70.85M34.06M-26.08M11.27M14.53M
Capital Expenditure424.00K424.00K2.80M7.95M3.69M4.41M5.37M3.08M114.00K00
Free Cash Flow-1.57M-4.13M-15.75M-27.19M-37.28M-41.73M-59.03M-68.14M-49.59M-11.41M-5.26M
Dividends Paid-0320.00K-----477.00K611.00K273.00K
FCF to OCF100.00%100.00%121.62%141.29%111.00%111.82%110.00%104.73%100.23%100.00%100.00%
Dividend Paid to FCF-0.00%-2.03%------0.96%-5.35%-5.19%

Earnings

Report DateMay 15, 2017Aug 14, 2017Nov 14, 2017Mar 29, 2018May 14, 2018Aug 13, 2018Nov 13, 2018Mar 18, 2019May 10, 2019Aug 9, 2019Nov 12, 2019Mar 16, 2020May 11, 2020Aug 10, 2020Nov 6, 2020Mar 24, 2021May 14, 2021Aug 16, 2021Nov 12, 2021Mar 23, 2022May 12, 2022Aug 11, 2022Nov 14, 2022Mar 29, 2023May 12, 2023Aug 14, 2023Nov 14, 2023Mar 11, 2024May 15, 2024Aug 13, 2024Nov 8, 2024Mar 28, 2025May 13, 2025Aug 8, 2025Nov 7, 2025Mar 10, 2026May 29, 2026Aug 5, 2026Nov 6, 2026
EPS Estimate----0.24-172.50-187.50-187.50-202.50-0.36-187.50-197.50-197.50-0.31-200.00-180.00-0.21-127.50-142.50-127.50-0.19-140.00-155.00-147.50-2.89-150.50-85.75-77.50-1.33-11.00-7.00-6.50-8.00-------
EPS Actual-0.14-0.21-0.27-0.61-180.00-142.50-210.00-330.00-0.34-217.50-187.50-307.50-0.28-240.00-172.50-0.32-142.50-120.00-142.50-0.22-150.00-142.50-135.00-2.70-103.00-100.00-69.81-0.86-23.00-12.00-2.003.63-0.95-0.19-0.07-0.07-0.14-0.16-
Surprise----154.17%-4.35%24.00%-12.00%-62.96%5.56%-16.00%5.06%-55.70%9.68%-20.00%4.17%-52.38%-11.76%15.79%-11.76%-15.79%-7.14%8.06%8.47%6.57%31.56%-16.62%9.92%35.34%-109.09%-71.43%69.23%145.38%-------
TimingAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hours------

Key Statistics & Ratios

Market Cap3.94M
Enterprise Value-13.39M
Trailing P/E0.00
Forward P/E0.00
Price / Sales2205.73
Price / Book0.51
EPS-0.42
Book Value0.996
Revenue (TTM)-50.00K
Gross Profit (TTM)0
EBITDA-3.50M
Profit Margin0.00%
Operating Margin0.00%
Return on Equity-58.12%
Return on Assets-15.36%
Shares Outstanding6.73M
Shares Float6.19M
Beta2.05
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 1 analystsTarget 10.00
  • Buy
    1

Ownership Breakdown

Institutions
9.93%
Insiders
8.02%
Retail / Other
82.05%

Top Institutional Holders

  • Kestra Advisory Services, LLC
    196.99K2.60%
  • Geode Capital Management, LLC
    92.79K1.22%
  • BlackRock Inc
    84.75K1.12%
  • Citadel Advisors Llc
    59.46K0.78%
  • CFO4Life Group, LLC
    33.51K0.44%
  • Vanguard Fiduciary Trust Co
    32.12K0.42%
  • Vanguard Capital Management, LLC
    25.70K0.34%
  • UBS Group AG
    3.66K0.05%
  • Tower Research Capital LLC
    1.90K0.03%
  • SBI Securities Co Ltd
    5090.01%
  • Morgan Stanley - Brokerage Accounts
    1180.00%
  • Cullen/Frost Bankers Inc
    130.00%
  • BNP Paribas Arbitrage, SA
    60.00%
  • JPMorgan Chase & Co
    20.00%
  • Citigroup Inc
    10.00%
  • Nbc Securities Inc
    30.00%

Top Fund Holders

  • Fidelity Extended Market Index
    34.04K0.45%
  • Fidelity Series Total Market Index
    4.18K0.06%
  • Fidelity Total Market Index
    1.08K0.01%
  • Nomura Healthcare Fund Class I
    1600.00%

Stock Splits

  • Jan 16, 20251:50
  • Apr 4, 20231:15